SUPPLEMENT
Q4 2023 — Financial disclosures
Q4 2023PDF · 10 pages1.1 MB
Merck & Co., Inc. Financial Highlights Package Fourth Quarter 2023 Table of Contents Table 1: GAAP P&L.....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter..................2 Table 2a: GAAP to Non-GAAP Reconciliation 4Q23 and Dec YTD 23.........3 Table 2b: GAAP to Non-GAAP Reconciliation 4Q22 and Dec YTD 22.. ......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 4Q23........................................................6 Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 23..............................................7 Table 3c: Sales – Pharmaceutical Geographic Split.....................................8 Table 4: Other (Income) Expense ..............................................................9 -- 1 of 10 -- Sales 14,630 $ 13,830 $ 6% 60,115 $ 59,283 $ 1% Costs, Expenses and Other Cost of sales 3,911 3,881 1% 16,126 17,411 -7% Selling, general and administrative 2,804 2,687 4% 10,504 10,042 5% Research and development 9,628 3,775 * 30,531 13,548 * Restructuring costs 255 49 * 599 337 78% Other (income) expense, net 78 (75) * 466 1,501 -69% (Loss) Income Before Taxes (2,046) 3,513 * 1,889 16,444 -89% Income Tax (Benefit) Provision (821) 495 1,512 1,918 Net (Loss) Income (1,225) 3,018 * 377 14,526 -97% Less: Net Income Attributable to Noncontrolling Interests 1 1 12 7 Net (Loss) Income Attributable to Merck & Co., Inc. (1,226) $ 3,017 $ * 365 $ 14,519 $ -97% (Loss) Earnings per Common Share Assuming Dilution (1) (0.48) $ 1.18 $ * 0.14 $ 5.71 $ -98% Average Shares Outstanding Assuming Dilution (1) 2,533 2,548 2,547 2,542 Tax Rate 40.1% 14.1% 80.0% 11.7% * 100% or greater (1) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 4Q23 4Q22 Full Year 2023 Full Year 2022 1 -- 2 of 10 -- Sales 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 $ 6% 1% Costs, Expenses and Other Cost of sales 3,926 4,024 4,264 3,911 16,126 5,380 4,216 3,934 3,881 17,411 1% -7% Selling, general and administrative 2,479 2,702 2,519 2,804 10,504 2,323 2,512 2,520 2,687 10,042 4% 5% Research and development 4,276 13,321 3,307 9,628 30,531 2,576 2,798 4,399 3,775 13,548 * * Restructuring costs 67 151 126 255 599 53 142 94 49 337 * 78% Other (income) expense, net 89 172 126 78 466 708 438 429 (75) 1,501 * -69% Income (Loss) Before Taxes 3,650 (5,335) 5,620 (2,046) 1,889 4,861 4,487 3,583 3,513 16,444 * -89% Income Tax Provision (Benefit) 825 637 870 (821) 1,512 554 538 330 495 1,918 Net Income (Loss) 2,825 (5,972) 4,750 (1,225) 377 4,307 3,949 3,253 3,018 14,526 * -97% Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 3 5 1 12 (3) 5 5 1 7 Net Income (Loss) Attributable to Merck & Co., Inc. 2,821 $ (5,975) $ 4,745 $ (1,226) $ 365 $ 4,310 $ 3,944 $ 3,248 $ 3,017 $ 14,519 $ * -97% Earnings (Loss) per Common Share Assuming Dilution (1) 1.11 $ (2.35) $ 1.86 $ (0.48) $ 0.14 $ 1.70 $ 1.55 $ 1.28 $ 1.18 $ 5.71 $ * -98% Average Shares Outstanding Assuming Dilution (1) 2,551 2,539 2,546 2,533 2,547 2,537 2,540 2,542 2,548 2,542 Tax Rate 22.6% -11.9% 15.5% 40.1% 80.0% 11.4% 12.0% 9.2% 14.1% 11.7% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 4Q Full Year (1) Because the company recorded a net loss in the second and fourth quarters of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. 2023 2Q 3Q 4Q Full Year 1Q 1Q 2Q 3Q 4Q Full Year 2022 Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2 -- 3 of 10 -- Fourth Quarter Cost of sales 3,911 $ 454 117 571 3,340 $ Selling, general and administrative 2,804 24 29 53 2,751 Research and development 9,628 790 790 8,838 Restructuring costs 255 255 255 – Other (income) expense, net 78 (35) (61) (96) 174 Loss Before Taxes (2,046) (1,233) (401) 61 (1,573) (473) Income Tax Provision (Benefit) (821) (227) (4) (67) (4) 13 (4) (281) (540) Net (Loss) Income (1,225) (1,006) (334) 48 (1,292) 67 Net (Loss) Income Attributable to Merck & Co., Inc. (1,226) (1,006) (334) 48 (1,292) 66 (Loss) Earnings per Common Share Assuming Dilution (5) (0.48) $ (0.40) (0.13) 0.02 (0.51) 0.03 $ Tax Rate 40.1% 114.2% Full Year Cost of sales 16,126 $ 2,018 211 2,229 13,897 $ Selling, general and administrative 10,504 86 122 208 10,296 Research and development 30,531 819 1 820 29,711 Restructuring costs 599 599 599 – Other (income) expense, net 466 (47) (279) 573 (3) 247 219 Income Before Taxes 1,889 (2,876) (933) 279 (573) (4,103) 5,992 Income Tax Provision (Benefit) 1,512 (476) (4) (155) (4) 60 (4) (60) (4) (631) 2,143 Net Income 377 (2,400) (778) 219 (513) (3,472) 3,849 Net Income Attributable to Merck & Co., Inc. 365 (2,400) (778) 219 (513) (3,472) 3,837 Earnings per Common Share Assuming Dilution 0.14 $ (0.94) (0.31) 0.08 (0.20) (1.37) 1.51 $ Tax Rate 80.0% 35.8% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (5) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Adjustment Subtotal Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non- GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect a $779 million in-process research and development (IPR&D) impairment charge related to gefapixant, which was obtained as part of the 2016 Afferent Pharmaceuticals acquisition, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, other (income) expense, net, for the full year includes a $37 million loss on the sale of a business. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items 3 -- 4 of 10 -- Fourth Quarter Cost of sales 3,881 $ 482 38 520 3,361 $ Selling, general and administrative 2,687 39 20 59 2,628 Research and development 3,775 740 740 3,035 Restructuring costs 49 49 49 – Other (income) expense, net (75) (69) 80 11 (86) Income Before Taxes 3,513 (1,192) (107) (80) (1,379) 4,892 Income Tax Provision (Benefit) 495 (222) (3) (32) (3) (13) (3) (267) 762 Net Income 3,018 (970) (75) (67) (1,112) 4,130 Net Income Attributable to Merck & Co., Inc. 3,017 (970) (75) (67) (1,112) 4,129 Earnings per Common Share Assuming Dilution 1.18 $ (0.38) (0.03) (0.03) (0.44) 1.62 $ Tax Rate 14.1% 15.6% Full Year Cost of sales 17,411 $ 2,059 205 2,264 15,147 $ Selling, general and administrative 10,042 176 94 270 9,772 Research and development 13,548 1,676 30 1,706 11,842 Restructuring costs 337 337 337 – Other (income) expense, net 1,501 (207) 1,348 1,141 360 Income Before Taxes 16,444 (3,704) (666) (1,348) (5,718) 22,162 Income Tax Provision (Benefit) 1,918 (809) (3) (129) (3) (294) (3) (1,232) 3,150 Net Income 14,526 (2,895) (537) (1,054) (4,486) 19,012 Net Income Attributable to Merck & Co., Inc. 14,519 (2,895) (537) (1,054) (4,486) 19,005 Earnings per Common Share Assuming Dilution 5.71 $ (1.14) (0.21) (0.42) (1.77) 7.48 $ Tax Rate 11.7% 14.2% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2022 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the fourth quarter and full year primarily reflect $780 million and $1.7 billion, respectively, of intangible asset impairment charges largely related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, and expenses for the amortization of intangible assets, partially offset by a reduction in expenses related to changes in the estimated fair value of liabilities for contingent consideration. Amounts included in other (income) expense, net, reflect royalty income and decreases in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal 4 -- 5 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2023 2022 4Q Full Year 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $14,487 $15,035 $15,962 $14,630 $60,115 $15,901 $14,593 $14,959 $13,830 $59,283 6 7 1 4 PHARMACEUTICAL 12,721 13,457 14,263 13,141 53,583 14,107 12,756 12,963 12,180 52,005 8 8 3 5 Oncology Keytruda 5,795 6,271 6,338 6,608 25,011 4,809 5,252 5,426 5,450 20,937 21 22 19 21 Alliance Revenue – Lynparza (2) 275 310 299 315 1,199 266 275 284 292 1,116 8 8 7 9 Alliance Revenue – Lenvima (2) 232 242 260 226 960 227 231 202 216 876 5 5 10 11 Welireg 42 50 54 72 218 18 27 38 40 123 79 78 77 77 Alliance Revenue – Reblozyl (3) 43 47 52 70 212 52 33 39 41 166 69 69 28 28 Vaccines (4) Gardasil / Gardasil 9 1,972 2,458 2,585 1,871 8,886 1,460 1,674 2,294 1,470 6,897 27 27 29 33 ProQuad / M-M-R II / Varivax 528 582 713 545 2,368 470 578 668 526 2,241 4 3 6 6 RotaTeq 297 131 156 185 769 216 173 256 139 783 34 33 -2 -1 Vaxneuvance 106 168 214 176 665 5 12 16 138 170 28 26 * * Pneumovax 23 96 92 140 85 412 173 153 131 145 602 -42 -43 -32 -31 Vaqta 40 42 69 29 180 36 35 64 39 173 -24 -25 4 4 Hospital Acute Care Bridion 487 502 424 429 1,842 395 426 423 441 1,685 -3 -3 9 11 Prevymis 129 143 157 175 605 94 103 114 118 428 49 49 41 43 Dificid 65 76 74 87 302 52 66 77 67 263 30 30 15 15 Zerbaxa 50 54 53 61 218 30 46 43 49 169 25 23 29 30 Noxafil 60 55 51 46 213 57 60 62 58 238 -21 -16 -11 -4 Primaxin 80 53 41 39 213 58 64 63 54 239 -28 -28 -11 -6 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 99 68 92 108 367 72 98 88 82 341 31 31 8 8 Adempas (6) 59 65 65 66 255 61 63 57 57 238 15 11 7 8 Virology Lagevrio 392 203 640 193 1,428 3,247 1,177 436 825 5,684 -77 -76 -75 -74 Isentress / Isentress HD 123 136 119 105 483 158 147 161 167 633 -37 -37 -24 -23 Neuroscience Belsomra 56 63 58 54 231 69 69 62 59 258 -8 -6 -11 -6 Immunology Simponi 180 180 179 171 710 186 181 173 166 706 3 -2 1 - Remicade 51 48 45 43 187 61 53 49 44 207 -1 -2 -9 -8 Diabetes (7) Januvia 551 511 581 547 2,189 779 756 717 561 2,813 -2 -2 -22 -20 Janumet 329 354 255 240 1,177 454 476 417 353 1,700 -32 -32 -31 -29 Other Pharmaceutical (8) 584 553 549 595 2,283 602 528 603 583 2,319 2 2 -2 - ANIMAL HEALTH 1,491 1,456 1,400 1,278 5,625 1,482 1,467 1,371 1,230 5,550 4 4 1 3 Livestock 849 807 874 808 3,337 832 826 829 814 3,300 -1 - 1 4 Companion Animal 642 649 526 470 2,288 650 641 542 416 2,250 13 12 2 3 Other Revenues (9) 275 122 299 211 907 312 370 625 420 1,728 -50 -1 -48 -15 *200% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $950 million, $951 million, $924 million and $876 million in the first, second, third and fourth quarter of 2023, respectively, and $1,305 million, $1,300 million, $1,231 million and $1,012 million in the first, second, third and fourth quarter of 2022, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively, and $114 million, $32 million, $10 million and $10 million in the first, second, third and fourth quarter of 2022, respectively. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $3,133 million, $3,557 million, $4,002 million and $2,962 million in the first, second, third and fourth quarter of 2023, respectively, and $2,481 million, $2,709 million, $3,552 million and $2,554 million in the first, second, third and fourth quarter of 2022, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. 5 -- 6 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FOURTH QUARTER 2023 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 4Q 2023 4Q 2022 % Change 4Q 2023 4Q 2022 % Change 4Q 2023 4Q 2022 % Change TOTAL SALES (1) $14,630 $13,830 6 $7,088 $6,279 13 $7,542 $7,551 - PHARMACEUTICAL 13,141 12,180 8 6,698 5,871 14 6,443 6,309 2 Oncology Keytruda 6,608 5,450 21 3,972 3,378 18 2,636 2,071 27 Alliance Revenue – Lynparza (2) 315 292 8 168 157 7 147 135 9 Alliance Revenue – Lenvima (2) 226 216 5 181 154 18 45 62 -28 Welireg 72 40 79 68 40 70 4 - Alliance Revenue – Reblozyl (3) 70 41 69 60 36 68 10 6 74 Vaccines (4) Gardasil / Gardasil 9 1,871 1,470 27 365 262 39 1,506 1,207 25 ProQuad / M-M-R II / Varivax 545 526 4 402 387 4 143 139 3 RotaTeq 185 139 34 112 82 37 73 57 28 Vaxneuvance 176 138 28 138 132 5 38 6 * Pneumovax 23 85 145 -42 22 66 -66 62 79 -21 Vaqta 29 39 -24 28 23 24 1 16 -94 Hospital Acute Care Bridion 429 441 -3 315 257 22 113 183 -38 Prevymis 175 118 49 78 52 49 98 65 50 Dificid 87 67 30 75 57 32 12 10 17 Zerbaxa 61 49 25 33 25 31 28 24 18 Noxafil 46 58 -21 4 13 -72 43 46 -7 Primaxin 39 54 -28 1 N/M 39 53 -27 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 108 82 31 102 85 20 6 -2 * Adempas (6) 66 57 15 66 57 15 Virology Lagevrio 193 825 -77 10 - 183 825 -78 Isentress / Isentress HD 105 167 -37 50 78 -36 56 89 -38 Neuroscience Belsomra 54 59 -8 21 19 10 33 39 -17 Immunology Simponi 171 166 3 171 166 3 Remicade 43 44 -1 43 44 -1 Diabetes (7) Januvia 547 561 -2 309 290 6 239 271 -12 Janumet 240 353 -32 41 97 -58 198 255 -22 Other Pharmaceutical (8) 595 583 2 144 180 -20 450 406 11 ANIMAL HEALTH 1,278 1,230 4 387 396 -2 891 834 7 Livestock 808 814 -1 158 188 -16 649 626 4 Companion Animal 470 416 13 229 208 10 242 208 16 Other Revenues (9) 211 420 -50 3 12 -75 208 408 -49 *200% or greater N/M - Not Meaningful (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $876 million in the fourth quarter of 2023 and $1,012 million in the fourth quarter of 2022. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $10 million in the fourth quarter of 2022. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,962 million in the fourth quarter of 2023 and $2,554 million in the fourth quarter of 2022. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FULL YEAR 2023 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International Full Year 2023 Full Year 2022 % Change Full Year 2023 Full Year 2022 % Change Full Year 2023 Full Year 2022 % Change TOTAL SALES (1) $60,115 $59,283 1 $28,480 $27,206 5 $31,635 $32,077 -1 PHARMACEUTICAL 53,583 52,005 3 26,539 24,989 6 27,044 27,016 - Oncology Keytruda 25,011 20,937 19 15,114 12,686 19 9,897 8,251 20 Alliance Revenue – Lynparza (2) 1,199 1,116 7 607 584 4 592 532 11 Alliance Revenue – Lenvima (2) 960 876 10 657 579 13 303 297 2 Welireg 218 123 77 209 123 70 10 - Alliance Revenue – Reblozyl (3) 212 166 28 168 123 37 43 43 1 Vaccines (4) Gardasil / Gardasil 9 8,886 6,897 29 2,083 2,065 1 6,803 4,832 41 ProQuad / M-M-R II / Varivax 2,368 2,241 6 1,837 1,724 7 531 518 3 RotaTeq 769 783 -2 493 508 -3 276 275 - Vaxneuvance 665 170 * 561 163 * 103 7 * Pneumovax 23 412 602 -32 127 346 -63 285 256 11 Vaqta 180 173 4 119 95 25 61 78 -21 Hospital Acute Care Bridion 1,842 1,685 9 1,156 922 25 686 762 -10 Prevymis 605 428 41 264 188 40 341 240 42 Dificid 302 263 15 274 241 14 28 22 25 Zerbaxa 218 169 29 119 89 33 100 79 25 Noxafil 213 238 -11 32 51 -37 181 187 -3 Primaxin 213 239 -11 1 1 -6 211 238 -11 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 367 341 8 350 329 6 16 12 41 Adempas (6) 255 238 7 255 238 7 Virology Lagevrio 1,428 5,684 -75 10 1,523 -99 1,418 4,161 -66 Isentress / Isentress HD 483 633 -24 215 274 -21 268 359 -25 Neuroscience Belsomra 231 258 -11 81 79 3 150 179 -16 Immunology Simponi 710 706 1 710 706 1 Remicade 187 207 -9 187 207 -9 Diabetes (7) Januvia 2,189 2,813 -22 1,151 1,248 -8 1,039 1,565 -34 Janumet 1,177 1,700 -31 223 355 -37 954 1,344 -29 Other Pharmaceutical (8) 2,283 2,319 -2 688 693 -1 1,596 1,628 -2 ANIMAL HEALTH 5,625 5,550 1 1,804 1,822 -1 3,821 3,728 2 Livestock 3,337 3,300 1 700 710 -1 2,637 2,590 2 Companion Animal 2,288 2,250 2 1,104 1,112 -1 1,184 1,138 4 Other Revenues (9) 907 1,728 -48 137 395 -65 770 1,333 -42 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $3,701 million and $4,848 million on a global basis for December YTD 2023 and 2022, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $118 million and $165 million on a global basis for December YTD 2023 and 2022, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $13,654 million and $11,297 million on a global basis for December YTD 2023 and 2022, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2023 2022 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year TOTAL PHARMACEUTICAL $12,721 $13,457 $14,263 $13,141 $53,583 $14,107 $12,756 $12,963 $12,180 $52,005 8 3 United States 6,117 6,570 7,153 6,698 26,539 6,773 5,726 6,620 5,871 24,989 14 6 % Pharmaceutical Sales 48.1% 48.8% 50.1% 51.0% 49.5% 48.0% 44.9% 51.1% 48.2% 48.1% Europe (1) 2,326 2,401 2,497 2,491 9,715 3,309 2,677 2,427 2,494 10,906 - -11 % Pharmaceutical Sales 18.3% 17.8% 17.5% 19.0% 18.1% 23.5% 21.0% 18.7% 20.5% 21.0% China 1,694 1,887 1,674 1,456 6,710 1,113 1,355 1,419 1,216 5,102 20 32 % Pharmaceutical Sales 13.3% 14.0% 11.7% 11.1% 12.5% 7.9% 10.6% 10.9% 10.0% 9.8% Japan 737 652 1,062 629 3,081 965 1,092 653 832 3,542 -24 -13 % Pharmaceutical Sales 5.8% 4.8% 7.4% 4.8% 5.7% 6.8% 8.6% 5.0% 6.8% 6.8% Asia Pacific (other than China and Japan) 703 705 636 616 2,661 786 854 702 691 3,034 -11 -12 % Pharmaceutical Sales 5.5% 5.2% 4.5% 4.7% 5.0% 5.6% 6.7% 5.4% 5.7% 5.8% Latin America 470 566 696 596 2,328 435 453 511 472 1,871 26 24 % Pharmaceutical Sales 3.7% 4.2% 4.9% 4.5% 4.3% 3.1% 3.6% 3.9% 3.9% 3.6% Eastern Europe/Middle East/Africa 381 370 301 299 1,351 450 339 360 320 1,469 -7 -8 % Pharmaceutical Sales 3.0% 2.7% 2.1% 2.3% 2.5% 3.2% 2.7% 2.8% 2.6% 2.8% Canada 141 127 133 138 540 189 166 166 158 678 -12 -20 % Pharmaceutical Sales 1.1% 0.9% 0.9% 1.1% 1.0% 1.3% 1.3% 1.3% 1.3% 1.3% Other 152 179 111 218 658 87 94 105 126 414 73 59 % Pharmaceutical Sales 1.2% 1.6% 0.9% 1.5% 1.4% 0.6% 0.6% 0.9% 1.0% 0.8% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 4Q23 4Q22 Full Year 2023 Full Year 2022 Interest income (70) $ (95) $ (365) $ (157) $ Interest expense 310 235 1,146 962 Exchange losses 162 17 370 237 (Income) loss from investments in equity securities, net (1) (99) 59 (340) 1,419 Net periodic defined benefit plan (credit) cost other than service cost (134) (71) (498) (279) Other, net (91) (220) 153 (681) Total 78 $ (75) $ 466 $ 1,501 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --